The prevalence of cardiac, renal, and metabolic conditions has significantly increased over 20 years and so has the number of US adults who have all 3.
Pivotal cardiovascular outcome trials that evaluated cardiorenal benefits of the newer classes were not designed to consider racial/ethnic variations, researchers state.